Evaluate TSHA stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in TSHA? | Glauxie AI

Q: What are the risks of investing in TSHA?

Taysha Gene Therapies, Inc. (TSHA) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Sean Nolan. Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central... Employees: 6,000.

Q: How much debt does TSHA have?

Review TSHA total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is TSHA a good long-term investment?

Evaluate TSHA as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in TSHA?

🦉

Taysha Gene Therapies, Inc. (TSHA)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOSean Nolan

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for...

Key Executives

Name	Title
Berge Minassian	Chief Medical Advisor of UT Southwestern Gene Therapy Program
David McNinch	Chief Commercial Officer
Emily McGinnis	Chief Patient & External Affairs Officer
Frederick Porter	Chief of Staff & Technical Operations Officer
Hayleigh Collins	Director of Corporate Communications & Investor Relations
Kamran Alam	Chief Financial Officer & Corporate Secretary

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

TSHA Profile Financials

Is TSHA stock safe? How much debt does TSHA have? Is TSHA a good long-term investment?